Appointment Progresses Company towards Global Goals

Stefan Fraenkel has been appointed CEO at pharmaceutical and service partner company Inceptua effective since January 1st.

Stefan, who has been leading the creation of one of the company’s three business units, Inceptua Pharma, since 2017 said : "I’m both humbled and proud to get this opportunity as we are growing and transforming Inceptua to further strengthen our position. I look forward to working closely with all parts of our business and competent teams to further develop Inceptua and help realise our ambition to be a global partner of choice for providing critical treatments to patients in need."

Chairman of the Board, Peter Krantz, said: "Stefan is an accomplished executive with a strong industry background focusing on commercial deal making, global marketing and sales, and corporate development. I look forward to continue the collaboration with Stefan in his new role as CEO as we take Inceptua to the next level."

With an MBA and a Ph.D. in international economics, Stefan joined the company in 2017 from Swedish Orphan Biovitrum AB (publ) (Sobi™) where he was Head of Corporate Development. He has also held various international commercial leadership positions in Europe and in the USA, while working at Wyeth/Pfizer.

The company also confirmed that Alan Raffensperger had joined the Board of Directors as Executive Vice-Chairman: "As we are growing our company there is a need to further formalise our Board structure. As such we are delighted to announce that Alan Raffensperger will join the Inceptua Board of Directors. During his tenure as CEO, Alan has successfully led Inceptua to where we are today – strongly positioned as a pharmaceutical company and leading service partner spanning throughout the product lifecycle. Over the past two years we have diversified our clinical trial services business, accelerated our early access program portfolio, and firmly established Inceptua Pharma. Alan will continue to play an active role in support of our business," added Peter Krantz.